Ejects of Single and Repeated Treatment with Itraconazole on the Pharmacokinetics of Midazolam in Rats

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 4, 2002, Pages 275-283

  Sawada, Yasufumi ^a   Takedomi, Sayuri ^a   Matsuo, Hirotami ^a   Ohtani, Hisakazu ^a   Yamano, Katsuhiro ^b   Iga, Tatsuji ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

cytochrome P450; drug interaction; itraconazole; midazolam; pharmacokinetics

Indexed keywords

EID: 33846869033     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.275     Document Type: Article

References (26)

1. Takedomi, S., Matsuo, H., Yamano, K., Yamamoto, K., Iga, T. and Sawada, Y.: Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug Metab. Dispos., 26: 318-323 (1998).
2. Yamano, K., Yamamoto, K., Kotaki, H., Sawada, Y. and Iga, T.: Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver. Drug Metab. Dispos., 27: 395-402 (1999).
3. Takedomi, S., Matsuo, H., Yamano, K., Ohtani, H. and Sawada, Y.: In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. J. Pharm. Pharmacol., 53: 643-651 (2001).
4. Jacobs, J. M., Nichols, C. E., Andrew, A. S., Marek, D. E., Wood, S. G., Sinclair, P. R., Wrighton, S. A., Kostrubsky, V. E. and Sinclair, J. F.: Eŝect of arsenite on induction of CYP1A, CYP2B and CYP3A in primary cultures of rat hepatocytes. Toxicol & Applied Pharmacol., 157: 51-59 (1999).
5. Ogg, M. S., Williams, J. M., Tarbit, M., Goldfarb, P. S., Gray, T. J. and Gibson, G. G.: A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica, 29: 269-279 (1999).
6. Zanger, R. C., Okita, J. R., Kim, H., Thomas, P. E., Anderson, A., Edwards, J. R., Springer, D. L. and Okita, R. T.: Eŝect of calcium channel antagonists nifedipine and nicardipine on rat cytochrome P-450 2B and 3A forms. J. Pharmacol. Exp. Ther., 290: 1436-1441 (1999).
7. Maurice, M., Pichard, L., Daujat, M., Fabre, I., Joyeux, H., Domergue, J. and Maurel, P.: Eŝects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J., 6: 752-759 (1992).
8. Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortiage, L. A., Brown, M. B., Guo, W. and Watkins, P. B.: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest., 99: 2545-2553 (1997).
9. Hostetler, J. N., Hanson, L. H. and Stevens, D. A.: Eŝect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother, 36: 477-480 (1992).
10. Kremers, P., Beaune, P., Cresteil, T., Graeve, J. D., Columelli, S., Leroux, J. P. and Gielen, J. E.: Cytochrome P-450 Monooxygenase activities in human and rat liver microsomes. Eur. J. Clin. Pharmacol., 118: 599-606 (1981).
11. Lowry, O., Rosebrough, N. J., Farr, A. L. and Randall, R. J.: Protein measurement with the flin phenol reagent. J. Biol. Chem., 193: 265-275 (1951).
12. Obach, R. S.: Prediction of human clearance of twentynine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecîc binding to microsomes. Drug Metabol. Dispos., 27: 1350-1359 (1999).
13. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn, 4: 879-885 (1981).
14. Laemmli, U. K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227: 680-685 (1970).
15. Nakamura, H., Sano, H., Yamazaki, M. and Sugiyama, Y.: Carrier-mediated active transport of histamine H2 receptor antagonist. Cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. J. Pharmacol. Exp. Ther., 269: 1220-1227 (1994).
16. Yamazaki, M., Suzuki, H. and Sugiyama, Y.: Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res., 13: 497-513 (1996).
17. Yamano, K., Yamamoto, K., Kotaki, H., Takedomi, S., Matsuo, H., Sawada, Y. and Iga, T.: Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats. Drug Metab. Dispos., 27: 1225-1231 (1999).
18. Yamano, K., Yamamoto, K., Kotaki, H., Takedomi, S., Matsuo, H., Sawada, Y. and Iga, T.: Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J. Pharmacol. Exp. Ther., 292: 1118-1126 (2000).
19. Takanaga, H., Ohnishi, A., Matsuo, H., Murakami, H., Sata, H., Kuroda, K., Urae, A., Higuchi, S. and Sawada, Y.: Pharmacokinetic analysis of felodipinegrapefruit interaction based on an irreversible enzyme inhibition model. Br. J. Clin. Pharmacol., 49: 49-58 (2000).
20. Kanamitsu, S., Ito, K., Green, C. E., Tyson, C. A., Shimada, N. and Sugiyama, Y.: Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res., 17: 419-426 (2000).
21. Wang, H. F., Figueiredopereira, M. E. and Correia, M. A.: Cytochrome P450 3A degradation in isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch. Biochem. Ciophys., 365: 45-53 (1999).
22. Robert, B. J.: Evidence of proteasome-mediated cytochrome P-450 degradation. J. Biol. Chem., 272: 9771-9778 (1997).
23. Correia, M. A., Davoll, S. H., Wrighton, S. A. and Thomas, P. E.: Degradation of rat liver cytochromes P450 3A after their inactivation by 3, 5-dicarbethoxy-2, 6-dimethyl-4-ethyl-1, 4-dihydropyridine: Characterization of the proteolytic system. Arch. Biochem. Biophys., 297: 228-238 (1992).
24. Higashikawa, F., Murakami, T., Kaneda, T. and Takano, M.: In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats. J. Pharm. Pharmacol., 51: 405-10 (1999).
25. Ludwig, E., Schmidt, J., Beschke, K. and Ebner, T.: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5?-methylhydroxylation by quinidine and hydroquinidine in vitro. J. Pharmacol. Exp. Ther., 290: 1-8 (1999).
26. Wang, J. S., Wen, X., Backman, J. T., Taavitsainen, P., Neuvonen, P. J. and Kivisto, K. T.: Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol. Toxicol., 85: 157-161 (1999).)